Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for FLT3 Ligand drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FLT3LG ECD-Fc / Monomer Recombinant Protein High purity (>95%), Endotoxin <1.0 EU/μg. Sequence Verified. HEK293 expressed for native glycosylation. |
View FLT3LG Products |
| Gene Delivery | FLT3LG Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and expression validation. |
View FLT3LG Products |
| Benchmark Ab | Anti-FLT3LG Neutralizing Antibody (NeutraControl / NeutraKine benchmark) Recombinant positive control for blocking and neutralization assays. |
View FLT3LG Products |
| Validator | FLT3LG siRNA Set For target knockdown verification and specificity profiling. |
View FLT3LG Products |
| Related Target A | FLT3 (CD135) The cognate receptor for FLT3LG. Critical for receptor-ligand binding kinetics and receptor tyrosine kinase activation assays. |
View FLT3 Products |
| Related Target B | KITLG (SCF) Synergistic cytokine in hematopoietic progenitor expansion and dendritic cell differentiation pathways. |
View KITLG Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Endotoxin-induced background noise in DC differentiation assays | Ultra-low endotoxin level (<1.0 EU/μg) verified by LAL assay to prevent non-specific immune cell activation. |
| Loss of native conformation in expression systems | HEK293 mammalian host expression ensures correct disulfide bond formation and native post-translational glycosylation. |
| Lack of reliable positive controls for neutralization | Sequence-verified clinical-grade benchmark neutralizing antibodies (NeutraControl/NeutraKine equivalent) included. |
| Off-target assay validation | High-specificity siRNA sets and homologous target proteins (KITLG/CSF1R) available for cross-reactivity screening. |
Live FLT3 Ligand R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic utilization of FLT3 Ligand (FLT3LG) is experiencing a significant renaissance. Historically recognized as a key hematological growth factor, FLT3LG has emerged as a cornerstone of next-generation cancer immunotherapies, particularly in the mobilization and recruitment of conventional type 1 dendritic cells (cDC1s) into the tumor microenvironment (TME). The race for FLT3LG-based therapeutics is intensifying, with major players shifting focus from traditional monotherapies to combination regimens with immune checkpoint inhibitors (such as anti-PD-1/PD-L1) and intratumoral administration strategies. As first-generation therapies reach the clinic, the next wave of R&D is targeting engineered FLT3LG fusion proteins with extended half-lives, tumor-localized activation profiles, and bispecific constructs that bridge dendritic cells directly to tumor-associated antigens.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Fc-Fusion Proteins (Long-acting) | Celldex Therapeutics, Amgen | Solid Tumors, Melanoma, AML | Binding Affinity & Receptor Activation (Requires high-purity FLT3 monomer and dimer antigens) |
| Cancer Vaccines / Adjuvants | Academic Medical Centers, Biotech Startups | Glioblastoma, Lymphoma | In vitro Dendritic Cell Mobilization assays (Requires endotoxin-controlled HEK293-expressed FLT3LG) |
| Neutralizing Antibodies / Antagonists | Autoimmune Disease Developers | Rheumatoid Arthritis, SLE | Neutralization Verification (Requires high-affinity NeutraControl/NeutraKine benchmark antibodies) |